[lurkingforacure]

At first glance, this article would not seem to have any bearing on PD per se, but then my skimming eye caught the words "glial activation" and I thought it worth posting. This might be something worth looking into for an off label use, and certainly the company looks like it might be heading in the right direction (and already approved in Japan 20 years ago with good safety record of use!). Here's the link:

http://www.globenewswire.com/newsroo....html?d=165755

In case you just read the article and dont' read the part that caught my eye: the details about the actual drug granted a US patent, and how it works:

AV411 is an orally bioavailable, CNS-penetrating, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to inhibit actions from toll-like receptor 4 (TLR4) stimulation and to antagonize a cytokine linked to systemic and neuroinflammation. These combined actions are thought to mediate its overall attenuation of neuroinflammation. While considered a New Molecular Entity (NME) in the United States and Europe, the drug was first approved in Japan nearly 20 years ago. The drug has been prescribed to over one million asthma patients and has a good post-marketing safety profile at the doses employed in Japan.